Navigation Links
Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Date:2/6/2008

-- Study concludes there was no evidence of the development of viral resistance to R7128 after 2 weeks of monotherapy in hepatitis C patients --

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Pharmasset (Nasdaq: VRUS) and Roche will present the R7128 monotherapy resistance profile at the EASL-AASLD-APASL-ALEH-IASL Conference on Hepatitis B & C Virus Resistance to Antiviral Therapies being held in Paris, France from February 14-16, 2008. The scientific abstract for poster board no. 36, entitled "Lack of Viral Resistance after 14-day Monotherapy Treatment with R7128 in Treatment-experienced Patients Infected with HCV Genotype 1," is currently available on the conference website at http://www.easl.ch/hepatitis-conference/program/session1.asp. The poster presentation will be available for download in PDF format after it is presented on February 14, 2008 in the "Events & Presentations" section of Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About R7128

R7128 is being developed for the treatment of chronic HCV infection through Pharmasset's collaboration with Roche. R7128 is a prodrug of PSI-6130, a nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule.

In a Phase 1 clinical trial, R7128 demonstrated potent, dose-dependent antiviral activity across four patient cohorts (n=40) receiving 750mg or 1500mg administered either once-daily or twice-daily for 2 weeks as monotherapy. The greatest mean decrease in HCV RNA from baseline was observed in the patient cohort that received 1500mg twice-daily, the highest dose of R7128 administered in the study. These patients experienced a mean 2.7 log10 IU/mL (>99%) decrease in HCV R
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche responds to announcement of IDEAL hepatitis C trial results
2. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
3. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
4. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
5. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
6. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
10. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
11. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Wash. , Dec. 19, 2014  Advanced ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that a Life ... has been awarded for which AMIC is the ... State University (WSU) for the proposal titled "Optimized ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. ... Kinetics Corp.) is pleased to provide this review of ... growth in 2015. "Over this past year, ... and I am extremely proud to say that Monarch ... today than it has ever been," stated Eric ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... 2010 Decision Resources, one of the world,s leading ... finds that the methicillin-resistant S taphylococcus aureus ... in 2009 to $752 million in 2019 in the ... Japan. The Pharmacor 2010 findings from the ...
... SAN DIEGO, Nov. 10, 2010 The American Council ... the largest nonprofit fitness certification, education and training organization ... national campaign that will focus on eliminating obesity in ... motivate consumers about the critical need to regularly engage ...
Cached Medicine Technology:Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019 2Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019 3American Council on Exercise (ACE) Announces Nationwide Effort to Eliminate Obesity in America 2American Council on Exercise (ACE) Announces Nationwide Effort to Eliminate Obesity in America 3
(Date:12/22/2014)... 2014 Coral Gables is preparing to welcome ... Troopers, with its new clinic location set to open in ... hassle out of dealing with this common childhood parasite by ... two salon clinic locations in South Florida, or in the ... decision to expand developed naturally out of the demand for ...
(Date:12/22/2014)... New York (PRWEB) December 22, 2014 The ... a staple of the season. Many may be thinking about ... a span of a few weeks. Health Republic Insurance of ... of Registered Dietitian, Andrea Chernus, to provide some smart ideas ... and stay healthy. , 1)    Avoid arriving at a holiday gathering ...
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Only weeks ... southern and mid-western cities to have a battery manufacturer ... TalkLocal ( http://www.talklocal.com ) is launching in Henderson ... economy. , “A strong manufacturing sector is going ... founder Gurpreet Singh explained, “and TalkLocal works with small ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... latest issue of Deutsches rzteblatt International ( ... research group presents epidemiological data. The authors surveyed ... specializing in the treatment of HIV patients in the ... to analyze the largest collection of data on the ...
... care information systems is a multibillion dollar industry. The ... to talk to each other regularly attract media comment. However ... Open Source, that could address many of these problems, because ... systems. Now new research by the University of Warwick,s ...
... Metabolomics is a post-genomic research field for analysis of ... approaches offer an analysis of metabolite level changes in ... in identifying the new diagnostic markers and therapeutic targets ... scarce. A research article to be published on ...
... an inflammatory obliterative cholangiopathy with unknown etiology, leading ... as an indispensable research tool for gene expression ... underlying BA, and allows the simultaneous analysis of ... studies have been performed to investigate the gene ...
... The best prescription for patients with venous leg ulcers is ... A five-year study led from the University of Leeds ... the healing process of leg ulceration contrary to what ... cheaper and easier to deliver, work just as well, the ...
... Reporter , MONDAY, March 7 (HealthDay News) -- Interactive ... kids, metabolisms to levels typically seen with moderate or ... the effect of six forms of so-called "exergaming" on ... (BMIs) at a youth fitness research and training center ...
Cached Medicine News:Health News:Resaerch finds open-source software is actually more secure for health care IT 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Video Games That Make Kids Move Burn Calories 2
Inquire...
Inquire...
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: